British researchers say they may have found a new treatment to tackle prostate cancer.
The new treatment would prevent the growth of the blood vessels that fuel the growth of a tumour.
The researchers at Bristol and Nottingham Universities have been studying the protein VEGF, vascular endothelial growth factor.
They believe they have found a way to reverse its effects so that it block the growth of blood vessels. They have achieved this by targeting a molecule called SRPK1.
Researcher Professor David Bates, from Nottingham, said: “This work opens up a new avenue for drug development for prostate cancer.
"This is a new target, and we believe we will be able to make drugs that hit this target in those patients that can benefit, with prostate cancer, and potentially other cancers too.”
The findings were welcomed by the charity Prostate Cancer UK.
Dr Matthew Hobbs, from the charity, said: "Although it’s early days, each finding like this represents a crucial block in building up our understanding of what can slow down and stop the progression of prostate cancer.
"This understanding will give us the foundations needed to develop new targeted treatments for those men in desperate need."
Serine arginine protein kinase-1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene 10 November 2014

Leave a Reply